HER2-positive Gastric Cancer
Conditions
Brief summary
To identify molecular biomarker panel correlating with efficacy of trastuzuamb in advanced HER2 positive gastric cancer patients. To observe the molecular evolution of HER2 positive gastric cancer during treatment by ctDNA detection.
Detailed description
Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
Interventions
GENETICctDNA screening
Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male/female patients aged over 18 years. 2. Histologically confirmed gastric adenocarcinoma. Gastric tumors should be treatment naïve unresectable or metastatic disease, or recurrence over 6 months after finish of adjuvant chemotherapy. 3. HER2 status is confirmed by IHC/FISH. HER2 positive: IHC 3+ or IHC 2+ plus FISH positive, HER2 negative: IHC 0/1+ or IHC 2+ plus FISH negative. 4. At least one measurable lesion should be confirmed by imaging examination. 5. Eligible peripheral blood samples 6. Patients with enough organ function and performance status (ECOG 0-2) can tolerant chemotherapy. 7. For HER2 positive patients, trastuzumab should be used as first-line treatment. The regimen of chemotherapy should be platinum plus oral fluorouracil. 8. For HER2 negative patients, clinicopathological characteristics should be matched to HER2 positive patients. 9. Willing to provide clinicopathological information and imaging information.
Exclusion criteria
1. Patients received systemic treatment before enrolled or finished adjuvant chemotherapy less than 6 months. 2. With second primary malignant diseases. 3. Other situations assessed by investigator can disturb quality control of the investigation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in molecular biomarkers at time on best overall response | 36 months | Molecular biomarkers including gene mutation, amplification and fusion were detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from patients during treatment. The list of genes included in OncoScreen Plus panelTM is provided as supplementary file. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in molecular biomarkers at time on disease progression | 36 months | Molecular biomarkers including gene mutation, amplification and fusion were detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from patients during treatment. The list of genes included in OncoScreen Plus panelTM is provided as supplementary file. |
Countries
China
Contacts
Primary ContactJing Liu
Backup ContactChenfei Zhou
Outcome results
None listed